Detalhe da pesquisa
1.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(4): 319-332, 2023 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36511784
2.
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
Lancet Oncol
; 25(1): 117-125, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38092009
3.
Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia.
Cancer
; 2024 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38578977
4.
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.
Blood
; 139(21): 3148-3158, 2022 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35303070
5.
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors.
Haematologica
; 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38235512
6.
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE.
Ann Hematol
; 2024 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38888616
7.
Discovery of a Novel and Potent LCK Inhibitor for Leukemia Treatment via Deep Learning and Molecular Docking.
J Chem Inf Model
; 2024 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38847742
8.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Future Oncol
; 20(12): 717-726, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38088119
9.
Targeting cytohesin-1 suppresses acute myeloid leukemia progression and overcomes resistance to ABT-199.
Acta Pharmacol Sin
; 45(1): 180-192, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37644132
10.
Upregulation of USP25 promotes progression of human diffuse large B-cell lymphoma through blocking the ubiquitinated degradation of MDM2.
Biochem Biophys Res Commun
; 676: 21-29, 2023 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37480689
11.
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.
Invest New Drugs
; 41(4): 606-616, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37420136
12.
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.
Am J Hematol
; 98(4): 571-579, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36683422
13.
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
Am J Hematol
; 98(11): 1742-1750, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37647123
14.
The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.
Hematol Oncol
; 39(5): 605-615, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34651869
15.
Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia.
Genet Med
; 19(2): 182-191, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27467457
16.
The polymorphisms of tumor necrosis factor-induced protein 3 gene may contribute to the susceptibility of chronic primary immune thrombocytopenia in Chinese population.
Platelets
; 27(1): 26-31, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-25806576
17.
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting.
Exp Hematol Oncol
; 13(1): 25, 2024 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38413984
18.
Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma.
Leuk Lymphoma
; 65(5): 647-652, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38557285
19.
A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapy.
Front Oncol
; 13: 1162413, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37256185
20.
Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma.
Front Oncol
; 13: 1193237, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37546390